A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients
可切除 HCC 患者新辅助治疗中双重 VEGF/PD-L1 阻断的 II 期和生物标志物研究
基本信息
- 批准号:10379391
- 负责人:
- 金额:$ 60.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:Adjuvant TherapyAdverse eventAreaBAY 54-9085BindingBiological MarkersBiopsyBlood VesselsCD8-Positive T-LymphocytesCatchment AreaCellsClinicalClinical ResearchCombined Modality TherapyDataEarly InterventionExcisionGeneral HospitalsGeographyGoalsHepatologyImageImmuneImmune responseImmunityImmunofluorescence ImmunologicImmunotherapyIn complete remissionIncidenceIndustryInstitutionInterventionLettersLigandsMRI ScansMalignant NeoplasmsMassachusettsMetabolicMethodist ChurchNecrosisNeoadjuvant StudyNeoadjuvant TherapyNivolumabOperative Surgical ProceduresOutcomePD-L1 blockadePathologicPathway interactionsPatientsPharmaceutical PreparationsPhasePilot ProjectsPlasmaPositron-Emission TomographyPre-Clinical ModelPrimary carcinoma of the liver cellsProspective cohortProtein ArrayRandomizedRandomized Clinical TrialsRecurrenceRegimenRegulatory T-LymphocyteResectableResectedRoleSafetySiteSpecimenSurvival RateT-LymphocyteTestingTimeTissuesToxic effectTumor ImmunityTumor TissueTumor-infiltrating immune cellsUnresectableVascular Endothelial Growth Factorsalpha-Fetoproteinsanti-PD-L1anti-cancerarmbasebevacizumabbiobankbiomarker signaturecancer cellcheckpoint receptorsclinical biomarkerscostcytokinedesigneffector T cellgenetic regulatory proteinimaging biomarkerimmune checkpointimprovedinnovationipilimumabliver cancer modelmortalitynovelobjective response ratepalliativeperipheral bloodphase 2 studyphase 3 studyphase III trialpreclinical studypredicting responseprimary endpointprogrammed cell death ligand 1programmed cell death protein 1responseroutine practicesecondary endpointsingle-cell RNA sequencingstandard of caresynergismtargeted treatmenttreatment armtrial designtumortumor-immune system interactions
项目摘要
SUMMARY
Surgical resection is curative in hepatocellular carcinoma (HCC). Unfortunately, surgical cases often suffer
from early recurrence (up to 50% in two years), which leads to dismal outcomes. Currently, there are no
approved neoadjuvant therapy options to induce pathologic response and reduce the rate of recurrence.
Notably, suppression of host immunity in HCC is a hallmark of cancer establishment and progression.
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor present on T-cells that binds to
specific ligands (PD-L1, PD-L2) on both tumor stroma and cancer cells. In preliminary studies, we have
analyzed resected HCC tissues after preoperative immunotherapy in early HCC. We found specific clusters
correlating with promising responses, including frequent pathologic complete responses at the time of
surgery (Cancer Immunol Res 2019). In addition, we demonstrated that PD-1 blockade can stabilize tumor
vasculature, thus enhancing anti-tumor immunity when combined with VEGF pathway blockade in
preclinical models of HCC (Hepatology 2020). Our goal is to show that reprogramming of immune
microenvironment in HCC will result in greater benefit for immunotherapy. We hypothesize that: 1)
Neoadjuvant anti-PD-L1/VEGF therapy is feasible, active and will induce pathologic complete response in resectable
HCCs, and 2) HCCs responding to neoadjuvant anti-PD-L1/VEGF therapy will have increased intratumoral CD8+
T-cell : Treg ratio, circulating cytokine levels, and favorable metabolic changes on imaging. We will test these
hypotheses in 2 specific aims: Aim 1: To evaluate the safety and efficacy of anti-PD-L1/VEGF combination therapy
in neoadjuvant setting in resectable HCC patients. This randomized, multi-site phase II clinical study will
accrue 90 patients based on 2:1 randomization (neoadjuvant atezo/bev = 60, versus upfront surgery = 30)
and has 2 sub-aims: Aim 1a will evaluate safety and pathologic response rate as the primary endpoints in
the atezo/bev arm; Aim 1b will evaluate 3-year recurrence-free survival rate and OS as secondary endpoints
in the atezo/bev arm versus control. Aim 2: To determine if activation of anti-tumor immunity correlates with
durable responses after dual anti-PD-L1/VEGF therapy in neoadjuvant setting in resectable HCC patients, which has
3 sub-aims through studying tissue, peripheral blood, and imaging parameters. Aim 2a is to analyze immune T-
cell clusters in pretreatment biopsies and posttreatment surgical resection specimens to evaluate CD8+ T-
cell : Treg ratio using multiplexed immunofluorescence and single cell RNA sequencing. Aim 2b is to study
changes in tissue immune cells, regulatory proteins, and plasma cytokines (multiplexed protein array) to
explore a biomarker signature that may predict response. Aim 2c is to evaluate correlation between
response and changes in tumor metabolic activity using PET MRI scan pre- and posttreatment. The impact
of this project is that it may transform the role of immunotherapy in HCC from palliative to curative.
总结
手术切除是治疗肝细胞癌(HCC)的有效方法。不幸的是,外科手术常常
早期复发(两年内高达50%),导致令人沮丧的结果。目前没有
批准的新辅助治疗方案,以诱导病理反应和降低复发率。
值得注意的是,HCC中宿主免疫的抑制是癌症建立和进展的标志。
程序性细胞死亡蛋白1(PD-1)是一种存在于T细胞上的免疫检查点受体,
肿瘤基质和癌细胞上的特异性配体(PD-L1、PD-L2)。在初步研究中,
分析了早期HCC术前免疫治疗后切除的HCC组织。我们发现了特定的集群
与有希望的反应相关,包括在治疗时频繁的病理完全反应。
手术(癌症免疫研究2019)。此外,我们证明PD-1阻断可以稳定肿瘤细胞,
血管,从而增强抗肿瘤免疫时,结合VEGF途径阻断,
HCC的临床前模型(Hepatology 2020)。我们的目标是证明免疫细胞的重编程
HCC微环境的改变将为免疫治疗带来更大的益处。我们假设:1)
新辅助抗PD-L1/VEGF治疗是可行的,积极的,并将诱导病理完全缓解,
HCC,和2)对新辅助抗PD-L1/VEGF治疗应答的HCC将具有增加的肿瘤内CD 8 +
T细胞:Treg比率、循环细胞因子水平和成像上有利的代谢变化。我们将测试这些
2个特定目的的假设:目的1:评价抗PD-L1/VEGF联合治疗的安全性和疗效
在可切除的HCC患者中进行新辅助治疗。这项随机、多中心II期临床研究将
基于2:1随机化招募90例患者(新辅助atezo/bev = 60例,而前期手术= 30例)
有2个子目标:目标1a将评价安全性和病理学缓解率作为主要终点,
atezo/bev组; Aim 1b将评价3年无复发生存率和OS作为次要终点
在atezo/bev组与对照组中的差异。目的2:确定抗肿瘤免疫的激活是否与
可切除的HCC患者在新辅助治疗背景下接受抗PD-L1/VEGF双重治疗后的持久应答,
通过研究组织、外周血和成像参数3个子目标。目的2a是分析免疫T-
在治疗前活组织检查和治疗后手术切除标本中的细胞簇,以评估CD 8 + T-
使用多重免疫荧光和单细胞RNA测序的细胞:Treg比率。目标2b是学习
组织免疫细胞、调节蛋白和血浆细胞因子的变化(多重蛋白阵列),
探索可以预测反应的生物标志物特征。目标2c是评估
在治疗前和治疗后,使用PET MRI扫描观察肿瘤代谢活性的反应和变化。的影响
该项目的一个重要意义在于,它可能将免疫疗法在HCC中的作用从姑息性转变为治愈性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HESHAM M AMIN其他文献
HESHAM M AMIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HESHAM M AMIN', 18)}}的其他基金
A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients
可切除 HCC 患者新辅助治疗中双重 VEGF/PD-L1 阻断的 II 期和生物标志物研究
- 批准号:
10614487 - 财政年份:2021
- 资助金额:
$ 60.87万 - 项目类别:
Role of IGF-IR tyrosine kinase in NPM-ALK-expressing T-cell lymphoma
IGF-IR 酪氨酸激酶在表达 NPM-ALK 的 T 细胞淋巴瘤中的作用
- 批准号:
8461921 - 财政年份:2011
- 资助金额:
$ 60.87万 - 项目类别:
Role of IGF-IR tyrosine kinase in NPM-ALK-expressing T-cell lymphoma
IGF-IR 酪氨酸激酶在表达 NPM-ALK 的 T 细胞淋巴瘤中的作用
- 批准号:
8291999 - 财政年份:2011
- 资助金额:
$ 60.87万 - 项目类别:
Role of IGF-IR tyrosine kinase in NPM-ALK-expressing T-cell lymphoma
IGF-IR 酪氨酸激酶在表达 NPM-ALK 的 T 细胞淋巴瘤中的作用
- 批准号:
8680025 - 财政年份:2011
- 资助金额:
$ 60.87万 - 项目类别:
Role of IGF-IR tyrosine kinase in NPM-ALK-expressing T-cell lymphoma
IGF-IR 酪氨酸激酶在表达 NPM-ALK 的 T 细胞淋巴瘤中的作用
- 批准号:
8847660 - 财政年份:2011
- 资助金额:
$ 60.87万 - 项目类别:
Role of IGF-IR tyrosine kinase in NPM-ALK-expressing T-cell lymphoma
IGF-IR 酪氨酸激酶在表达 NPM-ALK 的 T 细胞淋巴瘤中的作用
- 批准号:
8108296 - 财政年份:2011
- 资助金额:
$ 60.87万 - 项目类别:
Role of Jak3 in Anaplastic Large Cell Lymphoma
Jak3 在间变性大细胞淋巴瘤中的作用
- 批准号:
7145244 - 财政年份:2006
- 资助金额:
$ 60.87万 - 项目类别:
Role of Jak3 in Anaplastic Large Cell Lymphoma
Jak3 在间变性大细胞淋巴瘤中的作用
- 批准号:
7468066 - 财政年份:2006
- 资助金额:
$ 60.87万 - 项目类别:
Role of Jak3 in Anaplastic Large Cell Lymphoma
Jak3 在间变性大细胞淋巴瘤中的作用
- 批准号:
7275335 - 财政年份:2006
- 资助金额:
$ 60.87万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 60.87万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 60.87万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 60.87万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 60.87万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 60.87万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 60.87万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 60.87万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 60.87万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 60.87万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 60.87万 - 项目类别: